(S)-N-[4-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]benzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-N-[4-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]benzenesulfonamide
• 英文别名: L-739574；(S)-N-(4-(2-(2-hydroxy-3-(4-hydroxyphenoxy)propylamino)ethyl)phenyl)benzenesulfonamide；N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]benzenesulfonamide
• 化学式: C₂₃H₂₆N₂O₅S
• 分子量: 442.536
• InChiKey: KOKQDIGRUUTJDV-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-苄氧基苯酚 在 palladium dihydroxide 氢气 、 sodium hydride 作用下， 以 甲醇 为溶剂， 生成 (S)-N-[4-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]benzenesulfonamide
  参考文献：
  名称：

  Potent, selective benzenesulfonamide agonists of the human β3 adrenergic receptor

  摘要：

  A cloned human beta(3) adrenergic receptor assay was used to identify phenoxypropanolamine agonist 1. SAR studies led to the identification of benzenesulfonamide derivative 20, a 6.3 nM beta(3) agonist which shows 30-fold selectivity for beta(3) agonist activity over beta(1) and beta(2) receptor binding. Further refinement of this lead provided 4-bromo derivative 39, a subnanomolar agonist with 660-fold and 230-fold selectivity over beta(1) and beta(2), respectively. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00169-3

文献信息

• US5451677A
  申请人：——

  公开号：US5451677A

  公开（公告）日：1995-09-19
• Potent, selective benzenesulfonamide agonists of the human β3 adrenergic receptor
  作者：Ann E. Weber、Robert J. Mathvink、Leroy Perkins、Jennifer E. Hutchins、Mari R. Candelore、Laurie Tota、Catherine D. Strader、Matthew J. Wyvratt、Michael H. Fisher

  DOI：10.1016/s0960-894x(98)00169-3

  日期：1998.5

  A cloned human beta(3) adrenergic receptor assay was used to identify phenoxypropanolamine agonist 1. SAR studies led to the identification of benzenesulfonamide derivative 20, a 6.3 nM beta(3) agonist which shows 30-fold selectivity for beta(3) agonist activity over beta(1) and beta(2) receptor binding. Further refinement of this lead provided 4-bromo derivative 39, a subnanomolar agonist with 660-fold and 230-fold selectivity over beta(1) and beta(2), respectively. (C) 1998 Elsevier Science Ltd. All rights reserved.